Neurofibromatosis Market Size in 7MM is expected to witness a major change in the study period 2019-2032

The expected launch of therapies and the increasing Prevalent Cases will lead to the Neurofibromatosis market growth during the forecast period.

The Neurofibromatosis market report provides current treatment practices, emerging drugs, Neurofibromatosis market share of the individual therapies, current and forecasted Neurofibromatosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Neurofibromatosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Neurofibromatosis market.

Key takeaways from the Neurofibromatosis Market Report

• Neurofibromatosis Market Size is anticipated to increase during the study period, 2019-2032.

• As per Hackensack University Medical Center, Neurofibromatosis Prevalent Cases is highest for NF1.

• The leading Neurofibromatosis Companies includes AstraZeneca/Merck Sharp & Dohme LLC, Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., and others.

• Promising Neurofibromatosis Pipeline Therapies includes NFX-179 Gel, Mirdametinib, FCN-159, KOSELUGO (selumetinib), and others.

To discover which therapies are expected to grab the major Neurofibromatosis Market share, click here for Neurofibromatosis Market Research Report @ https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Neurofibromatosis Treatment Landscape

• FCN-159, developed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., is a highly active MEK1/2 inhibitor that was designed, synthesized, and screened based on the structure of trametinib. FCN-159 is orally available which is expected to be a targeted therapy for the treatment of advanced solid tumors and NF1. The drug is currently in Phase II clinical trial.

• SpringWorks Therapeutics' Mirdametinib is an orally administered, highly selective small-molecule inhibitor of the dual specificity kinases MEK1 and MEK2 (MAPK/ERK Kinase), which prevents the phosphorylation and subsequent activation of mitogen-activated protein kinase (MAPK). SpringWorks is conducting a Phase IIb clinical trial to evaluate the efficacy, safety, and tolerability of mirdametinib in patients two years of age and older with an inoperable NF1-PN that is causing significant morbidity. The drug has also been granted with FTD and ODD by the US FDA and the European Commission for the treatment of NF1.

Neurofibromatosis Overview

Neurofibromatosis (NF), a type of phakomatosis or syndrome with neurological and cutaneous manifestations, is a rare genetic disorder that typically causes benign tumors of the nerves and growths in other parts of the body, including the skin. Some people with this disorder have barely noticeable neurological problems, while others are affected profoundly. There are two major types: neurofibromatosis type I (NF1) and neurofibromatosis type II (NF2).

Neurofibromatosis Epidemiology Segmentation in the 7MM

• Total Neurofibromatosis Prevalent Cases

• Neurofibromatosis Type-specific Diagnosed Prevalent Cases

• Neurofibromatosis Diagnosed Prevalent Cases

• Neurofibromatosis Treatable Cases

Download the report to understand which factors are driving Neurofibromatosis Market Trends, click here for Neurofibromatosis Market Forecast @ https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neurofibromatosis Treatment Market

Treatment for brain tumors that are associated with NF1 depends on the characteristics of the tumor and the tumor location. Typically, treatment involves a combination of brain tumor surgery to resect the tumor, and radiation therapy or chemotherapy. While no treatment can reverse neurofibromatosis, its signs and symptoms can be addressed. Tumors, in particular, may warrant chemotherapy, radiation, surgery, or a combination of treatments. About 60% of people with NF1, symptoms are mild and can be monitored without needing treatment.

Neurofibromatosis Emerging Therapy Assessment
The Neurofibromatosis pipeline possesses potential drugs in mid- and late-stage developments. Key players like Fosun Pharmaceutical, SpringWorks Therapeutics, Inc., NFlection Therapeutics, Inc., and others hold the potential to create a significant positive shift in the Neurofibromatosismarket size.

Learn more about the Neurofibromatosis FDA-approved drugs, click here for Neurofibromatosis Treatment Market @ https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Neurofibromatosis Market Research Report

• Coverage- 7MM

• Neurofibromatosis Companies- AstraZeneca/Merck Sharp & Dohme LLC, Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., and others.

• Neurofibromatosis Pipeline Therapies- NFX-179 Gel, Mirdametinib, FCN-159, KOSELUGO (selumetinib), and others.

• Neurofibromatosis Market Dynamics: Neurofibromatosis Market Drivers and Barriers

Discover more about Neurofibromatosis Drugs in development, click here for Neurofibromatosis Market Drugs @ https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Neurofibromatosis
3. Competitive Intelligence Analysis for Neurofibromatosis
4. Neurofibromatosis: Market Overview at a Glance
5. Neurofibromatosis: Disease Background and Overview
6. Patient Journey
7. Neurofibromatosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Neurofibromatosis Unmet Needs
10. Key Endpoints of Neurofibromatosis Treatment
11. Neurofibromatosis Marketed Products
12. Neurofibromatosis Emerging Therapies
13. Neurofibromatosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Neurofibromatosis Market Outlook
16. Access and Reimbursement Overview of Neurofibromatosis
17. KOL Views
18. Neurofibromatosis Market Drivers
19. Neurofibromatosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Neurofibromatosis Market Dynamics of the report, click here for Neurofibromatosis Market Barriers and Drivers @ https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.